Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

News

Ardelyx will present 2 oral communications at the American Society of Nephrology Meeting in Philadelphia, November 2011


08/05/2011

–        Novel Non-Systemic NaP2b Inhibitors Block Intestinal Phosphate Uptake

Marc Navre*1, Eric Labonte1, Chris Carreras1, Andrew G. Spencer1, Joanne Marks2, Debbie Black1, Jason Lewis1, Jeffrey W. Jacobs1 and Dominique Charmot1, 1Ardelyx Inc., Fremont, CA, United States and 2University College London, London, United Kingdom

–        RDX5791, a Non-systemic NHE3 Inhibitor, Normalizes Blood Pressure and Reduces Salt-induced Organ Damage in Uremic Rats

Andrew G. Spencer*1, Marc Navre1, Craig F. Plato2, Kristin M Joly2, Eric Daniel Labonte1, Jeffrey W. Jacobs1 and Dominique Charmot1, 1Ardelyx, Inc., Fremont, CA, United States and 2Plato BioPharma, Inc., Westminster, CO, United States.



« back to news page